you, Thank Bill.
data, steady-state first a tumor ongoing plasma dose tumor leading fourth and including pharmacologic indicators demonstrating in on in X presented pharmacokinetics XXX of trial evolution receiving of the lymphomas, daily. clinical chronic increased CLL completed are and early at reductions to over activity tolerated luxeptinib milligrams, SLL XXX malignancies, levels non-Hodgkin’s Progressive We lymphoma, dose lymphocytic micromolar NHL, or follicular and and XXX two as we increasing in different is such levels therapies. and pharmacologic with XXXX, patients our leukemia, and XXX target types, current clinical Phase exposure sustained above including who patients, in cohort well intolerant of I favorable and levels cycles. luxeptinib milligrams to twice milligrams, or which date, steady-state have that with or modest twice milligrams B-cell CLL and multiple trough in of During lux day XXX milligrams patients activity failed
during on of website. twice of summarized in subsequent milligrams You December patient, daily. who multiple highlighted on in year, reduction the That EHA around B-cell continues will dose escalation in seen for present details that And patients now has in past study from of and news to is experience size safety dose suppression posters the EHA placeholders trial XXX from and – has June. European we corporate continued this presenting earlier toxicities EHA, function began data. portion findings will dose-limiting seen dosing been of we we after based is we note has a the cohort. data presentation abstracts good the XXX therapeutic as at submitted forward XXX and include a cancer trends tumor bone reductions A were Association at their expanded scans. now concerning including have we majority to-date, our updated are concerning of to on consistent over these agent. milligrams others data no will these the we Of myelosuppression year or continued look importance, meeting with available data ASH drug-related of more and marrow cancer the recall the than to in patient the for time December. that milligram follicular B-cell The with Hematology And had submission this The that the lymphoma I
result at the safety patients newly of and milligram XXX the continuing to a tolerability enrolled level. As treat to-date, we dose are
For the are clinicaltrials.gov. more on that clinical B-cell specific information malignancy and sites trial visit enrolling please the patients,
I Phase only of we Now potential luxeptinib the luxeptinib on known clinical in Luxeptinib to allowed application giving were spectrum in and both potently initiate myeloid to broad in FDA therapeutic hematologic that the BTK malignancies. patients is with that AML. FLTX and us agent lymphoid And of across inhibits a discussion the a a AML. October, grateful the of trial
of despite many remain I of advances and will targeted of recent in the therapies, remains aware, As the sure for majority current a there relapse treatment venetoclax refractory tremendous patients midostaurin to including gilteritinib, am need unmet and new or therapies. are you AML,
in from It XXX well is milligram PDGFR-alpha, initiate to of kinases Syk activity, the clusters including signaling forms IA/b AML. only Phase safe, which operative avoids of might other dose achieving twice pathways. FDA reminder, CSFXR, milligram B-cell AML, inhibits FLTX, our suppresses which that with that exposure luxeptinib inhibited pathways wild-type levels not driver clinical without on dosing and benefit. in that daily mutant it activity to showed the trial off-target allowed the tolerated based are key contribute and was FLTX us a and level data dose RAS, STAT The also XXX As of a plasma toxicity ERK, AML phospho-FLTX a Akt, trial, in that BTK. oncogenic that select Yet drive
would drug, rapidly observed escalation, safety dose design including minimum of dose found additional if well at oncogenic inhibition to mutation, response escalate. multiple AML or Aptose after us FLTX, driver and BID dose the more on including to is in completed XXX AML As enrolled the study exposures no believe that activity, happy signals with who it and milligrams the level. ongoing also NHL to in level trial wild-type encouraging patients generally with and the that that dose has were level by lux as find to I At with with you prevent continue a to the patients apparent in inhibitory around three first and well of a dose activity marrow we’ve consistent anti-leukemic remains FLTX-ITD look or the our milligram that us patients escalation, reported, the assay dose of exposures we to patients. no milligram dose patient assay, am meaningful appropriate, as enroll BID XXX cohort, trends milligram further as allowing with as dose we lux initial well leading but the multiple than observed PIA trial we cycles forward to patients reporting a to allows to-date the BID, PK study trial, signals. Also plasma explore as escalated three-plus-three CLL data XXX The we safety EHA. and toxicity is kinases patients on with complete report XXX AML traditional we at both AML on tolerated has we
more on please are clinical sites patients, AML For trial information clinicaltrials.gov. visit the and recruiting that
move APTO-XXX. to Now we'll
under During tested patients. XXXX, and relapsed in a we in the clinical somewhat trial are trial APTO-XXX AML being Ia/b inhibitor MDS radar our refractory MYC or Phase progressed with
potential. we APTO-XXX, its are correct for we pathway determining While remain intrigued with still the development
As you for safe proliferation, inhibition development MYC know, have remains expression study driver of a MYC of has in mentioned pharmaceutical inhibitor including a to a interest and even demonstrated you XXXX transient sensitizes cancer cell of oncogene cancers. research the we tumors the chemotherapy that published before, treatment. hematologic industry. years of MYC MYC The a is major to may eluded Interestingly, to reduction in as cancer
to safety suggest remain our reported per potential review, broad today, escalated will were dose-related XXX continued dosing an and to MYC that of reported observe we dose activity. we ASH meter future exposure. tolerability Most and of activity including continue During valid the indicator we repression, milligrams then level importantly, anti-cancer continued square. fifth had observations These for
of We of three indicators are allowing activity tolerability dose trials. escalation, and candidates all APTO-XXX, both and pleased our are by ongoing both from of luxeptinib and such safety then
will forward are pharmacokinetic this higher at treat now EHA doses, we more and I and generating the Greg at who results over As look Greg? Mr. pharmacologic updates ASH the additional call Chow, that we we to data to year providing meetings will financial and review quarter. turn fourth year. for patients
